278 related articles for article (PubMed ID: 8784096)
1. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study.
Hansen TB; Brixen K; Vahl N; Jørgensen JO; Christiansen JS; Mosekilde L; Hagen C
J Clin Endocrinol Metab; 1996 Sep; 81(9):3352-9. PubMed ID: 8784096
[TBL] [Abstract][Full Text] [Related]
2. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism.
Beshyah SA; Thomas E; Kyd P; Sharp P; Fairney A; Johnston DG
Clin Endocrinol (Oxf); 1994 Mar; 40(3):383-91. PubMed ID: 8187303
[TBL] [Abstract][Full Text] [Related]
3. Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency.
Kotzmann H; Riedl M; Bernecker P; Clodi M; Kainberger F; Kaider A; Woloszczuk W; Luger A
Calcif Tissue Int; 1998 Jan; 62(1):40-6. PubMed ID: 9405732
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; Di Nero G
J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
[TBL] [Abstract][Full Text] [Related]
5. Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism.
Ahmad AM; Thomas J; Clewes A; Hopkins MT; Guzder R; Ibrahim H; Durham BH; Vora JP; Fraser WD
J Clin Endocrinol Metab; 2003 Jun; 88(6):2860-8. PubMed ID: 12788900
[TBL] [Abstract][Full Text] [Related]
6. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
[TBL] [Abstract][Full Text] [Related]
7. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH.
Bengtsson BA; Edén S; Lönn L; Kvist H; Stokland A; Lindstedt G; Bosaeus I; Tölli J; Sjöström L; Isaksson OG
J Clin Endocrinol Metab; 1993 Feb; 76(2):309-17. PubMed ID: 8432773
[TBL] [Abstract][Full Text] [Related]
8. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
[TBL] [Abstract][Full Text] [Related]
9. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density in patients with growth hormone deficiency: does a gender difference exist?
Hitz MF; Jensen JE; Eskildsen PC
Clin Endocrinol (Oxf); 2006 Dec; 65(6):783-91. PubMed ID: 17121531
[TBL] [Abstract][Full Text] [Related]
11. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up.
Finkenstedt G; Gasser RW; Höfle G; Watfah C; Fridrich L
Eur J Endocrinol; 1997 Mar; 136(3):282-9. PubMed ID: 9100553
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.
Sneppen SB; Hoeck HC; Kollerup G; Sørensen OH; Laurberg P; Feldt-Rasmussen U
Eur J Endocrinol; 2002 Feb; 146(2):187-95. PubMed ID: 11834427
[TBL] [Abstract][Full Text] [Related]
13. Gender variation in PTH sensitivity and rhythmicity following growth hormone replacement in adult growth hormone-deficient patients.
White HD; Ahmad AM; Syed AA; Clewes A; Peter R; Vora JP; Fraser WD
Clin Endocrinol (Oxf); 2004 Apr; 60(4):516-26. PubMed ID: 15049968
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies.
Abrahamsen B; Hangaard J; Horn HC; Hansen TB; Gregersen G; Hansen-Nord M; Vahl N; Junker P; Andersen M; Hagen C
Clin Endocrinol (Oxf); 2002 Aug; 57(2):273-81. PubMed ID: 12153608
[TBL] [Abstract][Full Text] [Related]
15. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial.
Bex M; Abs R; Maiter D; Beckers A; Lamberigts G; Bouillon R
J Bone Miner Res; 2002 Jun; 17(6):1081-94. PubMed ID: 12054164
[TBL] [Abstract][Full Text] [Related]
16. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males.
Vandeweghe M; Taelman P; Kaufman JM
Clin Endocrinol (Oxf); 1993 Oct; 39(4):409-15. PubMed ID: 8287567
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
Gonc EN; Kandemir N
Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
[TBL] [Abstract][Full Text] [Related]
18. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group.
Longobardi S; Keay N; Ehrnborg C; Cittadini A; Rosén T; Dall R; Boroujerdi MA; Bassett EE; Healy ML; Pentecost C; Wallace JD; Powrie J; Jørgensen JO; Saccà L
J Clin Endocrinol Metab; 2000 Apr; 85(4):1505-12. PubMed ID: 10770189
[TBL] [Abstract][Full Text] [Related]
20. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
